Table 3

A1C at 26 weeks by treatment group

Treatment group
P
CGMControl
n6762
A1C*
    Baseline (%)6.4 ± 0.56.5 ± 0.3
    26 weeks (%)6.4 ± 0.56.8 ± 0.5
    Change from baseline to 26 weeks (%)+0.02 ± 0.45+0.33 ± 0.43
    Treatment group difference (%)−0.34 (−0.49 to −0.20)<0.001
    Decrease by ≥0.3% from baseline to 26 weeks21 (31)3 (5)<0.001
    Increase by ≥0.3% from baseline to 26 weeks19 (28)31 (52)0.002
    Subjects who maintained A1C <7.0 at 26 weeks59 (88)38 (63)<0.001
  • Data are means ± SD, difference (95% CI), or n (%).

  • *26-week A1C data were not available for 2 subjects in the control group.

  • †ANCOVA model adjusted for baseline A1C and site. The negative value denotes lower A1C in the CGM group compared with that in the control group.